Increasing Knowledge of Opioid Use Disorder and Medication Assisted Treatment in Advanced Practice Registered Nurses in Georgia

The national opioid crisis has had devastating effects on the United States (US) healthcare system with the financial burden totaling more than $2 trillion from 2015 to 2018 (White House Government, 2020) and the physical burden of 128 overdose-related deaths daily (Centers for Disease Control, 2020). According to the Centers for Disease Control (CDC), some of these deaths result from deficits in education of healthcare providers about pain management treatment (CDC, 2020). Improved education for healthcare providers has resulted in a significant decline in the total number of opioid prescriptions from 2016 to 2019, which suggests that successful containment of the opioid epidemic begins with the prescriber (White House Government, 2020). This paper will describe an online training module’s effectiveness in educating Advanced Practice Registered Nurses (APRNs) about medications used to treat opioid use disorder (OUD)

Increasing the Knowledge of Opioid Use Disorder and Medication Assisted Treatment for Advanced Practice Registered Nurses in Georgia

The national opioid crisis has had devastating effects on the United States (US) healthcare system with the financial burden totaling more than $2 trillion from 2015 to 2018 (White House Government, 2020) and the physical burden of 128 overdose-related deaths daily (Centers for Disease Control, 2020). According to the Centers for Disease Control (CDC), some of these deaths result from deficits in education of healthcare providers about pain management treatment (CDC, 2020). Improved education for healthcare providers has resulted in a significant decline in the total number of opioid prescriptions from 2016 to 2019, which suggests that successful containment of the opioid epidemic begins with the prescriber (White House Government, 2020). This paper will describe an online training module’s effectiveness in educating Advanced Practice Registered Nurses (APRNs) about medications used to treat opioid use disorder (OUD)

Increasing the Knowledge of Opioid Use Disorder (OUD) and Medication Assisted Treatment (MAT) in Advanced Practice Registered Nurses (APRNs) in Georgia

The national opioid crisis has had devastating effects on the United States (US) healthcare system with the financial burden totaling more than $2 trillion from 2015 to 2018 (White House Government, 2020) and the physical burden of 128 overdose-related deaths daily (Centers for Disease Control, 2020). According to the Centers for Disease Control (CDC), some of these deaths are the result of deficits in education to healthcare providers about pain management treatment (CDC, 2020). Improved education for healthcare providers has resulted in a significant decline in the total number of opioid prescriptions from 2016-2019 which suggests that successful containment of the opioid epidemic begins with the prescriber (White House Government, 2020). This paper will describe an online training module’s effectiveness to educate Advanced Practice Registered Nurses (APRNs) about medications used for treatment in opioid use disorder (OUD)

Safety, Pharmacodynamics, and Potential Benefit of Omaveloxolone in Friedreich Ataxia

Objective Previous studies have demonstrated that suppression of Nrf2 in Friedreich ataxia tissues contributes to excess oxidative stress, mitochondrial dysfunction, and reduced ATP production. Omaveloxolone, an Nrf2 activator and NF-kB suppressor, targets dysfunctional inflammatory, metabolic, and bioenergetic pathways. The dose-ranging portion of this Phase 2 study assessed the safety, pharmacodynamics, and potential benefit of omaveloxolone in Friedreich ataxia patients (NCT02255435). Methods Sixty-nine Friedreich ataxia patients were randomized 3:1 to either omaveloxolone or placebo administered once daily for 12 weeks. Patients were randomized in cohorts of eight patients, at dose levels of 2.5–300 mg/day. Results Omaveloxolone was well tolerated, and adverse events were generally mild. Optimal pharmacodynamic changes (noted by changes in ferritin and GGT) were observed at doses of 80 and 160 mg/day. No significant changes were observed in the primary outcome, peak work load in maximal exercise testing (0.9 ± 2.9 W, placebo corrected). At the 160 mg/day dose, omaveloxolone improved the secondary outcome of the mFARS by 3.8 points versus baseline (P = 0.0001) and by 2.3 points versus placebo (P = 0.06). Omaveloxolone produced greater improvements in mFARS in patients that did not have musculoskeletal foot deformity (pes cavus). In patients without this foot deformity, omaveloxolone improved mFARS by 6.0 points from baseline (P \u3c 0.0001) and by 4.4 points versus placebo (P = 0.01) at the 160 mg/day. Interpretation Treatment of Friedreich ataxia patients with omaveloxolone at the optimal dose level of 160 mg/day appears to improve neurological function. Therefore, omaveloxolone treatment is being examined in greater detail at 150 mg/day for Friedreich ataxia

Safety, Pharmacodynamics, and Potential Benefit of Omaveloxolone in Friedreich Ataxia

Objective Previous studies have demonstrated that suppression of Nrf2 in Friedreich ataxia tissues contributes to excess oxidative stress, mitochondrial dysfunction, and reduced ATP production. Omaveloxolone, an Nrf2 activator and NF-kB suppressor, targets dysfunctional inflammatory, metabolic, and bioenergetic pathways. The dose-ranging portion of this Phase 2 study assessed the safety, pharmacodynamics, and potential benefit of omaveloxolone in Friedreich ataxia patients (NCT02255435). Methods Sixty-nine Friedreich ataxia patients were randomized 3:1 to either omaveloxolone or placebo administered once daily for 12 weeks. Patients were randomized in cohorts of eight patients, at dose levels of 2.5–300 mg/day. Results Omaveloxolone was well tolerated, and adverse events were generally mild. Optimal pharmacodynamic changes (noted by changes in ferritin and GGT) were observed at doses of 80 and 160 mg/day. No significant changes were observed in the primary outcome, peak work load in maximal exercise testing (0.9 ± 2.9 W, placebo corrected). At the 160 mg/day dose, omaveloxolone improved the secondary outcome of the mFARS by 3.8 points versus baseline (P = 0.0001) and by 2.3 points versus placebo (P = 0.06). Omaveloxolone produced greater improvements in mFARS in patients that did not have musculoskeletal foot deformity (pes cavus). In patients without this foot deformity, omaveloxolone improved mFARS by 6.0 points from baseline (P \u3c 0.0001) and by 4.4 points versus placebo (P = 0.01) at the 160 mg/day. Interpretation Treatment of Friedreich ataxia patients with omaveloxolone at the optimal dose level of 160 mg/day appears to improve neurological function. Therefore, omaveloxolone treatment is being examined in greater detail at 150 mg/day for Friedreich ataxia